AZD-1480

DB12588InvestigationalSmall molecule

AZD1480 has been used in trials studying the treatment of Solid Malignancies, Post-Polycythaemia Vera, Primary Myelofibrosis (PMF), and Essential Thrombocythaemia Myelofibrosis.

Mechanism: Pharmacologically active on Tyrosine-protein kinase JAK2
Curator reviewed
Formula / weight: C₁₄H₁₄ClFN₈ · 348.766 g/mol (avg)
Code names: AZD-1480

Resolves to

Compound

UNIIKL2Z2TLF01CAS935666-88-9ChEMBLCHEMBL1231124PubChem16659841

Structure

InChIKeyPDOQBOJDRPLBQU-QMMMGPOBSA-NSMILESC[C@H](NC1=NC=C(Cl)C(NC2=NNC(C)=C2)=N1)C1=NC=C(F)C=N1

Targets

O60674JAK2

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with AZD-1480, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account